Drug intelligence / Profile preview

68Ga-exendin

Development stage: Unknown
Lead developer: Radboud University Medical Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration: Intravenous

Overview

68Ga-exendin (specifically 68Ga-exendin-4) is a radiolabeled peptide-based diagnostic imaging agent used in positron emission tomography (PET) / computed tomography (CT) scans. It consists of exendin-4, a stable synthetic analog of glucagon-like peptide-1 (GLP-1), conjugated to a chelator (such as NODAGA, DOTA, or NOTA) and labeled with the positron-emitting radioisotope gallium-68 ($^{68}\text{Ga}$). The tracer binds with high affinity to the glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed on pancreatic beta cells and benign insulinomas. It is primarily used for the preoperative localization of insulinomas, the detection of focal congenital hyperinsulinism (CHI) in pediatric patients, and the non-invasive monitoring of transplanted pancreatic islets in patients with type 1 diabetes.

Other names: 68Ga-DO3A-VS-Cys40-exendin-468Ga-DOTA-exendin-468Ga-HBED-CC-exendin-468Ga-NODAGA-exendin-468Ga-NOTA-exendin-468Ga-NOTA-MAL-Cys39-exendin-468Ga-NOTA-MAL-Cys40-exendin-468Ga-exendin-4[68Ga]Ga-NODAGA-exendin-4[68Ga]exendin-4gallium-68-labeled exendin-4gallium68-labeled exendin-4gallium 68-labeled exendin-4

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on 68Ga-exendin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-exendin.